Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021

SELL
$6.5 - $10.53 $1,488 - $2,411
-229 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$3.7 - $7.66 $847 - $1,754
229 New
229 $1,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Capital Asset Advisory Services LLC Portfolio

Follow Capital Asset Advisory Services LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Asset Advisory Services LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Asset Advisory Services LLC with notifications on news.